BiotechTube

olaratumab + ramucirumab

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Adult Glioblastoma Multiforme

Conditions

Adult Glioblastoma Multiforme

Trial Timeline

Jul 1, 2010 → Mar 4, 2014

NCT ID
NCT00895180

About olaratumab + ramucirumab

olaratumab + ramucirumab is a phase 2 stage product being developed by Eli Lilly for Adult Glioblastoma Multiforme. The current trial status is completed. This product is registered under clinical trial identifier NCT00895180. Target conditions include Adult Glioblastoma Multiforme.

What happened to similar drugs?

9 of 20 similar drugs in Adult Glioblastoma Multiforme were approved

Approved (9) Terminated (2) Active (11)
✅BenralizumabAstraZenecaApproved
✅FluMist + inactivated influenza vaccineAstraZenecaApproved
✅Saizen® solution for injection (referred as Saizen®)MerckApproved
✅Tacrolimus/Sirolimus + Tacrolimus/MMF + Neoral/SirolimusRocheApproved
✅Aztreonam lysineGilead SciencesApproved
✅maraviroc + Raltegravir + Darunavir/ritonavirPfizerApproved
✅SabrilLundbeckApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00895180Phase 2Completed

Competing Products

20 competing products in Adult Glioblastoma Multiforme

See all competitors
ProductCompanyStageHype Score
BBP-398 + sotorasibBridgeBio PharmaPhase 1
18
Daridorexant + PlaceboIdorsiaPhase 1
23
SON-1010 (IL12-FHAB)Sonnet BioTherapeuticsPhase 1
23
SomatropinEli LillyPhase 3
40
agenT-797MiNK TherapeuticsPhase 1
19
PegilodecakinEli LillyPhase 1
29
eFT226 + Sotorasib + Fulvestrant + Abemaciclib + TrastuzumabeFFECTOR TherapeuticsPhase 1/2
29
Lazertinib(G001) + Lazertinib(G002)YuhanPhase 1
29
Patritumab deruxtecanDaiichi SankyoPhase 2
27
DJ-927 + capecitabineDaiichi SankyoPhase 1
29
Valemetostat TosylateDaiichi SankyoPhase 2
35
RoxadustatAstellas PharmaPhase 1
29
ASP3325 + PlaceboAstellas PharmaPhase 1
29
TRK-100STPAstellas PharmaPhase 1
29
EnsitrelvirShionogiPhase 1
29
E6130 + PlaceboEisaiPhase 1
29
E7389 + E7389 + E7389EisaiPhase 1
29
Eribulin MesylateEisaiPhase 1
29
E2022 + E2022 + E2022 + E2022 + E2022EisaiPhase 1
29
Donepezil Hydrochloride + Donepezil Hydrochloride + Donepezil Hydrochloride + Donepezil HydrochlorideEisaiPhase 1
29